Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Mutation.
Connection Strength

0.708
  1. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017 Nov 01; 72(11):3100-3107.
    View in: PubMed
    Score: 0.125
  2. Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. J Chemother. 2017 Aug; 29(4):220-226.
    View in: PubMed
    Score: 0.117
  3. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents. 2014 Oct; 44(4):301-5.
    View in: PubMed
    Score: 0.100
  4. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.064
  5. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006 Dec; 58(6):1185-92.
    View in: PubMed
    Score: 0.058
  6. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003 Oct; 52(4):616-22.
    View in: PubMed
    Score: 0.047
  7. Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid. J Antibiot (Tokyo). 2018 05; 71(5):514-521.
    View in: PubMed
    Score: 0.032
  8. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016 Mar; 71(3):678-84.
    View in: PubMed
    Score: 0.027
  9. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015 Sep; 46(3):313-8.
    View in: PubMed
    Score: 0.027
  10. Antibiotic Development and the Evolving Role of Pharmacodynamics - As Good as It Gets? EBioMedicine. 2015 Jul; 2(7):615-6.
    View in: PubMed
    Score: 0.027
  11. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013 Oct; 57(10):4956-62.
    View in: PubMed
    Score: 0.023
  12. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother. 2013 Apr; 68(4):881-7.
    View in: PubMed
    Score: 0.022
  13. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.021
  14. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003 May; 47(5):1604-13.
    View in: PubMed
    Score: 0.011
  15. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015 Dec 07; 60(3):1208-15.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.